Sun Pharma Advanced Research Company Limited — PPTs, 19-12-2024: Investor Presentation

**Investor Presentation Summary**

**Financial Highlights:** SPARC is focusing on cost optimization, expecting a ~30% reduction in manpower expenses as they reorganize teams and streamline operations. The financial implications aim to extend their runway through better alignment of objectives and operational efficiency.

**Strategic Initiatives and Growth Drivers:** The company is prioritizing its oncology and immunology portfolios with assets like SBO-154 and SCD-153. Both products are believed to hold significant potential for market impact upon validating their clinical hypotheses. SPARC is also open to innovative partnering structures to enhance their asset development.

**Business Developments:** The PROSEEK study for Vodobatinib in early Parkinson’s disease did not meet its primary endpoint, prompting a shift to medium-term clinical proof of concepts to ensure continued pipeline viability. Upcoming milestones include numerous IND filings and progressing towards pivotal Phase 1 and Phase 2 studies.

**Market Position and Competitive Advantage:** With a strategic focus on first-in-class assets, including targeted therapies leveraging advanced ADC technology, SPARC aims for differentiation in an increasingly competitive landscape. The ongoing research emphasizes niche markets such as prostate cancer, chronic dermatological diseases, and specific oncology indications.

**Investor Implications:** Close attention is advised on the evolving clinical pipeline, particularly for SCD-153, which targets Alopecia Areata, and SBO-154 in cancer therapy, both of which may unlock significant shareholder value as they progress through clinical stages. Potential collaboration opportunities and strategic partnerships could further enhance SPARC's market positioning and drive growth.